title: [Some comparative aspects of treating the gastroesophageal reflux disease eradication].
abstract: At present proton pump inhibitors have been the most efficient drugs for treating the gastroesophageal reflux disease (GERD). Pariet may be selected as a drug for treating all forms of GERD as it requires smaller doses and shorter treatment period to obtain the clinical and endoscopic remission. Upon the clinical and endoscopic remission, patients need a supportive treatment. Different patients need various supportive treatment schemes. Our goal comes to the provision of the maximum efficiency of the schemes when prescribing the minimum doses of the drug.
authors.forename: O N
authors.initials: ON
authors.lastname: Minushkin
authors.forename: L V
authors.initials: LV
authors.lastname: Maslovskiĭ
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Anikina
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001562:Benzimidazoles / Q000627:therapeutic use*; D016099:Endoscopy, Gastrointestinal; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors; D064750:Rabeprazole
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D009853:Omeprazole